Reference
Chai, X., Hu, L., Zhang, Y., et al. (2020). Specific ACE2 Expression in
Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection.
bioRxiv. 02.03.931766. doi:10.1101/2020.02.03.931766
Chen, N., Zhou, M., Dong, X., et al. (2020). Epidemiological and
clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia
in Wuhan, China: a descriptive study. Lancet. 395(10223), 507-513.
doi:10.1016/S0140-6736(20)30211-7.
Gurwitz, D. (2020). Angiotensin receptor blockers as tentative SARSCoV-2
therapeutics. Drug Development Research. 1–4.
Imai, Y., Kuba, K., Rao, S., et al. (2005). Angiotensin-converting
enzyme 2 protects from severe acute lung failure. Nature. 436,112-116.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. (2020). SARS-CoV-2
Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically
Proven Protease Inhibitor. Cell. 181(2),271-280.e8.
doi:10.1016/j.cell.2020.02.052
Paz Ocaranza, M., Riquelme, J.A., García, L., et al. (2020).
Counter-regulatory renin–angiotensin system in cardiovascular disease.
Nature Reviews Cardiology. 17(2),116-129. doi:10.1038/s41569-019-0244-8.
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J.J.V., Pfeffer,
M.A., Solomon, S.D. (2020). Renin–Angiotensin–Aldosterone System
Inhibitors in Patients with Covid-19. New England Journal of Medicine.
doi:10.1056/nejmsr2005760
Zhang, P., Zhu, L., Cai, J., et al. (2020). Association of Inpatient Use
of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor
Blockers with Mortality Among Patients With Hypertension Hospitalized
With COVID-19. Circulation Research. doi:10.1161/circresaha.120.317134
Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression
profiling of ACE2, the putative receptor of Wuhan 2019-nCov.bioRxiv . 2020:2020.01.26.919985. doi:10.1101/2020.01.26.919985
Zhou, P., Yang, X., Wang, X., et al. (2020). A pneumonia outbreak
associated with a new coronavirus of probable bat
origin. Nature .579, 270–273. doi:10.1038/s41586-020-2012-7.